Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well bortezomib with or without irinotecan works in
treating patients with gastroesophageal junction or stomach cancer that can not be removed by
surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth. Drugs used in chemotherapy such as irinotecan use different ways to stop
tumor cells from dividing so they stop growing or die. Combining bortezomib with irinotecan
may kill more tumor cells.